IMFINZI® (durvalumab) plus tarlatamab demonstrated a statistically significant and highly clinically meaningful improvement in overall survival and progression-free survival in 1st-line extensive-stag
AstraZeneca's IMFINZI (durvalumab) plus Amgen's tarlatamab showed statistically significant improvements in overall survival and progression-free survival in a Phase III trial for extensive-stage small cell lung cancer. The trial included patients who had not progressed after initial treatment. Results will be shared with regulators and presented at a medical meeting.
How this was made
The 30-second read
Why it matters
The trial met its primary OS endpoint with statistically significant improvement, suggesting a new standard of care.
Market read
First disclosure of pivotal trial data for two major biotech firms; likely to move their stocks and influence the oncology sector.
What to watch
Regulatory timelines and competition from other bispecifics could temper immediate price impact.
Background
The DeLLphi‑305 Phase III trial evaluated IMFINZI plus tarlatamab versus IMFINZI alone in first‑line maintenance for extensive‑stage small‑cell lung cancer.
Ticker impact
AstraZeneca's IMFINZI (durvalumab) showed a significant overall survival benefit when combined with Amgen's tarlatamab in a Phase III ES‑SCLC trial.
potential upside of 5‑10% over the next weeks
Phase III results are material, first disclosure, and address an unmet need in small‑cell lung cancer.
Amgen's bispecific T‑cell engager tarlatamab contributed to the survival improvement in the DeLLphi‑305 trial with IMFINZI.
potential upside of 4‑8% in the short term
First public read‑out of a pivotal trial for tarlatamab, a key asset for AMGN.
Market effects
strengthens the oncology/biotech sector outlook, especially for checkpoint inhibitor combos.
positive for US and European biotech markets where AZN and AMGN are listed.
global relevance as ES‑SCLC is a worldwide unmet need.
Counterpoint
Skeptics may question durability of OS benefit and potential safety concerns before regulatory approval.
Key entities
- CompanyAstraZeneca
Manufacturer of IMFINZI (durvalumab).
- CompanyAmgen
Developer of tarlatamab, the bispecific T‑cell engager.
